BML Capital Management LLC Grows Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

BML Capital Management LLC lifted its stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 13.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,462,079 shares of the company’s stock after acquiring an additional 662,079 shares during the period. Atea Pharmaceuticals accounts for approximately 12.6% of BML Capital Management LLC’s holdings, making the stock its 3rd biggest position. BML Capital Management LLC owned approximately 6.55% of Atea Pharmaceuticals worth $16,659,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Gladius Capital Management LP boosted its stake in Atea Pharmaceuticals by 98.2% during the third quarter. Gladius Capital Management LP now owns 8,581 shares of the company’s stock valued at $26,000 after buying an additional 4,251 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Atea Pharmaceuticals by 351.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,653 shares of the company’s stock valued at $29,000 after purchasing an additional 7,514 shares in the last quarter. Pinnacle Wealth Planning Services Inc. acquired a new position in shares of Atea Pharmaceuticals in the 3rd quarter worth approximately $49,000. Barclays PLC grew its stake in shares of Atea Pharmaceuticals by 67.8% in the 3rd quarter. Barclays PLC now owns 25,619 shares of the company’s stock worth $77,000 after purchasing an additional 10,348 shares during the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of Atea Pharmaceuticals by 17.7% in the 3rd quarter. Principal Financial Group Inc. now owns 30,392 shares of the company’s stock worth $91,000 after purchasing an additional 4,574 shares in the last quarter. 86.67% of the stock is currently owned by institutional investors.

Insider Activity

In other Atea Pharmaceuticals news, insider Andrea Corcoran sold 15,843 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $3.84, for a total transaction of $60,837.12. Following the sale, the insider now owns 670,208 shares in the company, valued at approximately $2,573,598.72. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Atea Pharmaceuticals news, insider Andrea Corcoran sold 15,843 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $3.84, for a total value of $60,837.12. Following the completion of the transaction, the insider now directly owns 670,208 shares in the company, valued at $2,573,598.72. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Jean-Pierre Sommadossi sold 56,910 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $3.85, for a total transaction of $219,103.50. Following the completion of the transaction, the chief executive officer now owns 116,557 shares of the company’s stock, valued at $448,744.45. The disclosure for this sale can be found here. Insiders sold a total of 85,230 shares of company stock valued at $327,852 over the last three months. Insiders own 14.50% of the company’s stock.

Atea Pharmaceuticals Stock Performance

Shares of NASDAQ:AVIR opened at $3.73 on Wednesday. The stock has a market capitalization of $313.95 million, a price-to-earnings ratio of -2.27 and a beta of 0.16. Atea Pharmaceuticals, Inc. has a 1-year low of $2.77 and a 1-year high of $5.19. The company has a 50 day moving average price of $3.99 and a 200 day moving average price of $3.52.

Atea Pharmaceuticals (NASDAQ:AVIR) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.03). On average, sell-side analysts expect that Atea Pharmaceuticals, Inc. will post -2.76 EPS for the current fiscal year.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.